Recent Research Analysts’ Ratings Updates for Bristol Myers Squibb (BMY)

Bristol Myers Squibb (NYSE: BMY) recently received a number of ratings updates from brokerages and research firms:

• 7/10/2026 – Bristol Myers Squibb had its price target lowered by Bank of America Corporation from $67.00 to $66.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $54.00 price target on the stock.
• 7/2/2026 – Bristol Myers Squibb had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 6/27/2026 – Bristol Myers Squibb was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/6/2026 – Bristol Myers Squibb was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/28/2026 – Bristol Myers Squibb had its “buy” rating reaffirmed by UBS Group AG.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.